Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.
about
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1Tumor-specific Th17-polarized cells eradicate large established melanomaHarnessing the Microbiome to Enhance Cancer ImmunotherapyEnhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoproteinImmunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapyAdministration of cyclophosphamide changes the immune profile of tumor-bearing miceTumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsCD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors.Assumptions of the tumor 'escape' hypothesis.Cancer vaccines: progress reveals new complexities.Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cellsPossibilities for active immunotherapy of human cancer.CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.CD4 cells can be more efficient at tumor rejection than CD8 cellsAntigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.Interleukin 7 induces CD4+ T cell-dependent tumor rejection.Toll-like receptors in tumor immunotherapy.Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cellsImmunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunityToxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemiaFBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens.An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues.Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function.Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progressionThe central role of CD4(+) T cells in the antitumor immune response.Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour modelInduction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
P2860
Q24633445-938B9B56-604A-4778-A9FD-768A039DB242Q24648032-D15B9E8C-F65D-4D91-9720-35EBFD8A1D3AQ28088598-6AD31B59-4D24-42F8-AE6D-368A4A264570Q28383234-95573D2C-BA20-477B-816E-8ECD38645C15Q30371547-4DC54611-B7E2-4ACD-9A1F-09428F9856E0Q30533257-9C74C32C-971C-4D73-8776-18996D7276D7Q33552626-D3A10F07-9ACE-4DFF-8439-64988731771CQ33611809-C437CFB5-E56D-47C2-9292-AF816450652DQ33730171-893E08E1-438A-44D3-B4B4-B339EF6C37C5Q33867018-8BF88BDA-8958-4B68-9029-543930B2430EQ34103645-2CAE013D-A3F1-4FA0-BFBB-EED2A7FCE200Q34243372-BC0BC371-F4DE-4607-8F4B-28CBEFAA4C2CQ34418112-428815F1-4559-47B0-959D-EF7EDE5233C8Q34494018-BE4B985C-B563-4266-B932-E3FFF032C1EDQ34568823-A3CF05D2-D688-418B-A723-691340535BFEQ34583258-F26145D6-703E-4060-A75C-77C3781D8AADQ34774541-C67AD709-9A44-40B2-BAD8-1D6178AA41AAQ35071850-60BFB175-7A8B-42CC-9C7E-8859197DB8E9Q35326752-916CF038-9BAC-4028-80FC-CF86347F1751Q35558644-50218C26-5FD6-4C0F-892D-84ED5BF52D50Q35789284-4B6A1F4D-5B92-4BB5-BE0D-75BF13D5CB65Q35839925-997422F4-4E11-4B25-A0BA-797A26D0F203Q36093442-2EC9578B-7C40-4664-AEF1-16D51A817B3BQ36230021-8D167770-B059-40B7-9856-FF7BB2937306Q36230708-782E3EB7-E563-42CB-902D-C67F0D189B36Q36253608-524633B8-7127-4DBF-B316-AB572A81FC58Q36351792-D1C947FB-6222-461A-9D6E-F5DB1D238AD8Q36355782-3B13D89F-48A5-4250-AC4E-07AEC0CF069AQ36355851-CD9C4EB0-C3F4-41E1-8973-6DE18C1D7860Q36355924-9E3579CE-373C-4217-ABFE-EEE3D59D39A3Q36361846-A20AD245-6B70-44DC-82B0-CC8E6B04B7FDQ36367841-39359CF2-D98F-47EF-9881-8FF4807D2DD4Q36369462-AAA757F3-9331-484E-9A25-2B9C769031CAQ36369713-2A9735AB-2D42-43E9-AFBF-6F0F961669B6Q36375248-4B04F5D0-CE75-43ED-819A-58F7876D95E5Q36399807-92B1C95C-B4D3-4FF0-BE85-6912CF32E3AFQ36401381-D5AE10BF-E5CC-460E-8125-A957E18A4882Q36454472-454DF4EF-01E4-4FE5-8509-24E2A8C89F4FQ36466665-CEB15AC8-21F9-4C8E-9E6A-DF08A27FC749Q36509692-D113CE14-AE87-40BE-BD28-D0A59579EB15
P2860
Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
Therapy of disseminated murine ...... cipation of cytotoxic T cells.
@ast
Therapy of disseminated murine ...... cipation of cytotoxic T cells.
@en
type
label
Therapy of disseminated murine ...... cipation of cytotoxic T cells.
@ast
Therapy of disseminated murine ...... cipation of cytotoxic T cells.
@en
prefLabel
Therapy of disseminated murine ...... cipation of cytotoxic T cells.
@ast
Therapy of disseminated murine ...... cipation of cytotoxic T cells.
@en
P2093
P2860
P356
P1476
Therapy of disseminated murine ...... cipation of cytotoxic T cells.
@en
P2093
M A Cheever
P D Greenberg
P2860
P304
P356
10.1084/JEM.161.5.1122
P407
P577
1985-05-01T00:00:00Z